Venrock

Venrock is one of the oldest and most respected venture firms in the United States, founded in 1969 as the venture capital arm of the Rockefeller family and now operating as an independent partnership headquartered in Palo Alto with offices in New York and Cambridge. The firm has invested in healthcare since its earliest days and has produced a track record across therapeutics, devices, and digital health that few peers can match. Venrock’s healthcare franchise is anchored by senior partners Bryan Roberts and Bob Kocher, who together have built one of the most active and intellectually rigorous healthcare practices in venture, with a portfolio that combines value-based care services, digital health platforms, AI-native clinical tools, and selected biotech assets.

Bryan Roberts, a longtime partner and one of the most-followed investors in the digital health category, currently sits on the boards of Aledade (the value-based primary care enabler), Devoted Health (the Medicare Advantage insurer), Element Biosciences, Encoded Therapeutics, Included Health, Lyra Health, Moonlight Bio, SmithRx, and Suki.ai (the AI medical scribe). Bob Kocher, a partner and former Obama administration health policy advisor, brings clinical and policy depth to the practice, and his current board roles include Devoted Health, Virta Health, Aledade, Lyra Health, Need, Accompany Health, Candid, and Aligned Marketplace. The pair have publicly framed their thesis as moving away from one-trick-pony health tech point solutions and toward platform companies that have a credible plan to scale from $20 million to $250 million in revenue, an analytical lens that founders should internalize before pitching.

The broader Venrock partnership includes generalist and healthcare-focused partners across the firm’s other practices, including enterprise software, security, and consumer. Past Venrock healthcare investments include athenahealth (IPO and subsequent transactions), Castlight Health (IPO), Illumina (early backer; IPO and dominant genomics franchise), and a deep roster of digital health and therapeutics names. The firm operates with a small partnership and a relatively concentrated portfolio, prizing depth of engagement over volume of deals.

Venrock typically writes initial checks of $5 million to $20 million across Series A and B, with the capacity to lead and co-lead at both stages and to follow on into Series C and growth. The firm prefers to lead at Series A and frequently writes the first or second institutional check in healthcare companies, particularly those with strong founder-market fit and a credible commercial plan. Geographic scope is United States with selective international deals, and a strong network density in San Francisco, New York, Boston, and Washington DC.

Founders who should approach Venrock are operators building platform-scale digital health and value-based care companies, AI-native clinical and operational tools with a defensible data wedge, and selected therapeutics or devices with strong scientific and commercial differentiation. Repeat operators with prior healthcare exits will find a particularly receptive audience, as will academic founders with translational programs. Founders building point solutions, consumer DTC brands without a clinical wedge, or pure healthcare services without scaling potential should pitch other firms. Roberts and Kocher have been explicit that they are looking for category-defining companies, not feature businesses.

Entry path runs through warm introductions from portfolio CEOs, the broader Venrock alumni network, peer venture firms, and the senior healthcare operating community. Roberts and Kocher are publicly active at HLTH, ViVE, JPMorgan Healthcare, AcademyHealth, and major policy and clinical conferences. Both contribute frequently to Fortune, the Health Care Blog, and other industry publications, and Kocher in particular runs a personal blog (bobkocher.org) that signals his thinking. Cold inbound through the website is read but converts at low rates without a strong commercial proof or warm referral. Diligence is rigorous and partner-driven, typically four to eight weeks from first meeting to term sheet for competitive deals.

In a pitch, lead with the platform thesis, the commercial wedge, and the path from current scale to $250 million in revenue. Venrock partners are operators and clinicians and they will probe your unit economics, your customer concentration, your sales motion, and your competitive positioning in detail. They will also test your team and your operating plan. The firm’s added value is most powerful when founders use the deep Venrock platform: senior operating talent, the firm’s policy connections in Washington, the Bryan Roberts and Bob Kocher healthcare community, and downstream introductions to peer growth investors. Founders building category-defining digital health and value-based care companies will find Venrock one of the most intellectually rigorous and operationally useful tier-one partners in the entire healthcare landscape.